Role of Litigation in Defining Drug Risks_JAMA / BMJ
Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.
Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.
Readers of the New England Journal of Medicine should be forewarned: The information in the pages of the NEJM is tainted by industry influence, its professional and scientific integrity are tainted.
The question is: will Eli Lilly succeed, once again, to divert public attention from the revelations contained in its internal documents about the company's illegal marketing practices and its failure to warn about lethal risks posed by its product?
NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation."
An eye opening article by Jeanne Lenzer, “NIH Secrets,” in The New Republic (below), should make the new Congress sit up and take notice!
FDA's slip-shod approval of defective, harmful drugs, accompanied by rubber stampped endorsements by compromised FDA advisory committees may be reaching a boiling point.
The ethics of this radical drug experiment is being challenged by Dr. Jerald Block, a forthright psychiatrist and experienced system's analyst. His critical appraisal, published in the Bioethics Forum, Hastings Center Report.
The Whistleblower: Confessions of a Healthcare Hitman by Dr. Peter Rost, published by Soft Skull Press.
Two surveys confirm medical researchers' resistance to complying with conflict of interest disclosure requirements.
Medical researchers who commit fraud and research misconduct are caught only when a person of conscience steps up to the plate and blows the whistle. There are no systemic, independent checks and balances to prevent research fraud or abuse of patients.
BBC PANORAMA TONIGHT – Taken on Trust – 13 years-Medical Deception Sun, 3 Oct 2004 BBC-Panorama is airing its third in a series of investigative reports about the betrayal of trust in psychiatry, drug manufacturers and government regulators. The first program, The Secret of Seroxat, aired October 13, 2002, revealed…
Credibility Crisis:Survey FDA Scientists – Death in NIH-AIDS Trial – Tauzin Moves to PhRMA Thu, 16 Dec 2004 A credibility crisis in medical research is smoldering: like the Enron accounting scandal, the prescription-drug debacle is a matter of systemic corruption, including gross and widespread failure by the regulatory process. Unlike…